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ABSTRACT
Carbapenemase-producing Enterobacteriaceae (CPE) are an important and increasing threat to
global health. Both clonal spread and plasmid-mediated transmission contribute to the ongoing rise
in incidence of these bacteria. Among the 4 classes of b-lactamases defined by the Ambler
classification system, the carbapenemases that confer carbapenem resistance in Enterobacteriaceae
belong to 3 of them: Class A (K. pneumoniae carbapenemases, KPC), Class B (metallo-b-lactamases,
MBL including New Delhi metallo-b-lactamases, NDM) and Class D (OXA-48-like carbapenemases).
KPC-producing CPE are the most commonly occurring CPE in the United States. MBL-producing CPE
have been most commonly associated with the Indian Subcontinent as well as with specific
countries in Europe, including Romania, Denmark, Spain, and Hungary. The epicenter of OXA-48-
like-producing is in Turkey and surrounding countries. Detailed knowledge of the epidemiology and
molecular characteristics of CPE is essential to stem the spread of these pathogens.
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Introduction
Resistance against antibacterials in clinically relevant
bacteria is one of the most imminent threats to public
health and especially to our most vulnerable patient pop-
ulations. The World Health Organization has recognized
antimicrobial resistance (AMR) as “a global health secu-
rity threat that requires action across government sectors
and society as a whole.” 1 The Centers for Disease Con-
trol and Prevention (CDC) has estimated the excess
direct healthcare costs associated with AMR to be as
high as $20 billion, and additional costs to society for
lost productivity as high as $35 billion a year in the
United States alone.2 Reliable global estimates are needed
for the proportion of total infections that are caused by
multidrug resistant (MDR) bacteria, and the proportion
for each bacterial species isolated from clinical samples
that displays an MDR phenotype. However, obtaining
the data to calculate these proportions is hampered by
incomplete reporting, practice variance in diagnostics
and changing definitions for the MDR phenotype. None-
theless, important progress in this respect has been made
by organizations such as various tracking programs led
by the CDC (www.cdc.gov), the Centers for Disease
Dynamics, Economics and Policy (CDDEP, www.cddep.
org), the Antibacterial Resistance Leadership Group
(ARLG, www.arlg.org), and in Europe by the European
Centers for Disease Control and Prevention (eCDC,
ecdc.europa.eu) and the Combatting Bacterial Resistance
in Europe project (COMBACTE, www.combacte.com).
Enterobacteriaceae are a family of bacteria that encom-
pass many bacteria that are commonly isolated from
clinical cultures, including Escherichia coli, Klebsiella spp.,
and Enterobacter spp. From the perspective of antimicro-
bial resistance, Enterobacteriaceae are especially important
as they are a common cause of community-associated as
well as healthcare-associated infections.3
In recent years, we have witnessed the emergence of
carbapenemase-producing Enterobacteriaceae (CPE).
For now, infections caused by CPE in the US are gener-
ally healthcare-associated, although community-associ-
ated infections are beginning to emerge.3,4 The threat of
CPE is substantial as carbapenems have traditionally
been used in the treatment of infections caused by
extended-spectrum b-lactamase-producing Enterobac-
teriaceae (ESBL-E), and are still considered a last-line of
defense against Enterobacteriaceae to date. Few antibiot-
ics retain activity against CPE due to the ability of carba-
penemases to hydrolyze most other b-lactam antibiotics
as well as the frequent coexistence in CPE isolates of
additional mechanisms of resistance against other antibi-
otic classes such as fluoroquinolones and aminoglyco-
sides. The remaining therapeutic options are less than
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desirable secondary to concerns over the lack of efficacy
and their toxicity profiles.5 In addition, rates of resistance
to these agents of last resort such as tigecycline and poly-
myxins are increasing.6-9 Recently, ceftazidime-avibac-
tam has become available and other novel agents with
anti-CPE activity are in phase 3 clinical trials.10 Nonethe-
less, it is likely that history will repeat itself and resistance
against these newer agents will also develop in time.
In this review, we describe the current epidemiology
of CPE.
Definitions and terminology
In the past, the field of antibacterial resistance research
has been plagued by the lack of standardized definitions
for resistance phenotypes. In 2012, Magiorakos and
colleagues proposed consensus definitions for MDR,
extensively-drug-resistant (XDR) and pandrug-resistant
(PDR) bacteria, generated by experts representing the
CDC and eCDC.11 Using these criteria, almost all cur-
rently encountered CPE would be considered MDR, and
a substantial subset of CPE would be considered XDR.
Additional issues with terminology have been
introduced by the concurrent use of the terms carbape-
nem-resistant Enterobacteriaceae (CRE), CPE and
carbapenemase-producing carbapenem-resistant Entero-
bacteriaceae (CP-CRE). Also, the terms carbapenem-resis-
tant organisms (CRO) and carbapenemase-producing
organisms (CPO) are occasionally used. The CDC had ini-
tially defined CRE as those Enterobacteriaceae which were
non-susceptible to  1 carbapenem and were resistant to
3rd generation cephalosporins. In their November 2015
update, this definition was revised. CRE are now defined as
any Enterobacteriaceae which are resistant (excluding inter-
mediate resistance) to any carbapenem antimicrobial or are
documented to produce a carbapenemase. In addition, for
those Enterobacteriaceae which may have intrinsic reduced
susceptibility to imipenem such as Proteus mirabilis, resis-
tance to a non-imipenem carbapenem is required.12 The
CDC acknowledges that this definition lacks specificity for
CPE, especially in low-prevalence areas. The CDC Toolkit
therefore recommends that laboratories confirm carbape-
nemase production by performing molecular testing for the
presence of carbapenemases. In this review, we will specifi-
cally focus on the epidemiology of CPE.
Horizontal gene transfer and clonal expansion
An important question that remains largely unresolved is
whether the main driver of spread of carbapenemases
within Enterobacteriaceae is clonal expansion and trans-
mission of successful CPE clonal lineages that stably
maintain carbapenemase genes, or whether horizontal
transfer of carbapenemase genes through mobile genetic
elements such as plasmids containing them is primarily
responsible. The global spread of sequence type (ST) 258
KPC-producing K. pneumoniae is an argument in favor
of the former.13,14 ST258 K. pneumoniae is considered a
“high risk international clone,” similar to ST131 E. coli.15
In addition, specific clades within ST258 have been asso-
ciated with carriage of specific blaKPC genes: ST258A –
corresponding to clade I – is found to be highly associ-
ated with blaKPC-2 whereas ST258B (clade II) tends to
carry blaKPC-3.
16 This suggests that through recombina-
tion events and transference of mobile genetic elements,
including transposons and plasmids, blaKPC-2 and
blaKPC-3 have become associated with specific clones of
K. pneumoniae, and that this association has remained
intact as bacteria spread from one person to the next.
These subtypes also differ in the genetic region responsi-
ble for capsular polysaccharide biosynthesis.
However, evidence for outbreaks primarily related to
horizontal gene transfer has also been reported. In a 5-
year single center CPE outbreak investigation, blaKPC
was found in 66 different strains of Enterobacteriaceae.
These 66 strains consisted of 13 different species, includ-
ing Klebsiella, Enterobacter, and Citrobacter.17 In addi-
tion to person-to-person spread of blaKPC carrying
bacteria, they found evidence for the transfer of plasmids
between various bacteria, as well as for the transfer of
blaKPC containing transposons between plasmids.
17 In
addition, an outbreak investigation from Norway
revealed that intergenous spread mediated through a
blaKPC-2 containing plasmid was responsible for trans-
mission of carbapenem resistance from K. pneumoniae
to Enterobacter asburiae.18
It is clear that there is continuous interplay between
bacterial clones and mobile genetic elements that carry
resistance genes. In contrast to the close association
between ST258 and blaKPC, blaOXA-48 is is more closely
associated with IncLM type plasmids irrespective of ST
type.15 In conclusion, both plasmid-mediated spread
that involves horizontal transmission of resistance genes
between bacteria, as well as clonal expansion and trans-
mission likely contribute to the ongoing global CPE epi-
demic. Evidence is strong that clonal expansion is
responsible for a substantial portion of transmitted cases.
However, plasmid-mediated transmission is harder to
detect and may have been underestimated in reports to
date.
Where are CPE found?
Among the 4 classes of b-lactamases defined by the
Ambler classification system, the carbapenemases that
confer carbapenem resistance in Enterobacteriaceae
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belong to 3 of them: Class A, Class B, and Class D.19
Class A enzymes include the Klebsiella pneumoniae car-
bapenemase (KPC) family, as well as much less com-
monly encountered nonmetallocarbapenemase type A
(NMC-A) and SME enzymes, which may be found in E.
cloacae and S. marcescens, respectively. KPC enzymes are
the most commonly encountered enzymatic cause for
carbapenem resistance in the US. The closely related
genes blaKPC-2 and blaKPC-3 account for most of blaKPC.
Class B enzymes include the metallo-b-lactamases
(MBL), such as the New-Delhi-metallo-b-lactamases
(NDM), the IMP family of carbapenemases, and the Ver-
ona integron–encoded metallo-b-lactamases (VIM). In a
zinc-dependent manner, these enzymes hydrolyze a
broad variety of b-lactams, but are unable to hydrolyze
monobactams such as aztreonam. Class D carbapene-
mases produced by Enterobacteriaceae include the oxa-
cillinase (OXA)-48-like b-lactamases. OXA-48-like
carbapenemases in isolation induce a relatively weak
hydrolysis of penicillins and carbapenems but not cepha-
losporins. As a consequence they may be more difficult
to detect, and have been called “the phantom menace.”20
Unfortunately, high level carbapenem resistance may
occur when these enzymes are found in combination
with other b-lactamases such as ESBL, or with porin
changes leading to permeability defects.
Where are KPC-producing CPE found?
Carbapenemases of the KPC family have the most exten-
sive global distribution of all carbapenemases associated
with Enterobacteriaceae. The first KPC-producing CPE
in the United States was isolated from a patient in North
Carolina.21 This strain was identified through the Project
Intensive Care Antimicrobial Resistance Epidemiology
(ICARE) of the CDC, another example of the importance
of such surveillance programs.22 This initial report was
followed by a large number of cases of KPC-producing
CPE reported from New York City area hospitals.14 In a
New York-based multicenter survey, the prevalence of
blaKPC within K. pneumoniae isolates peaked at 36% in
2006.23 Of great interest, a notable decline has since been
recorded to 25% in 2009 and 13% in 2013–2014.23
Spread to the Great Lakes region of the United States has
been described. The Consortium on resistance against
carbapenems in Klebsiella and other Enterobacteriaceae
(CRACKLE) is a prospective, multicenter, observational
study of hospitals in Ohio, Pennsylvania and Michigan.16
Data from CRACKLE showed endemicity of KPC-pro-
ducing CPE, primarily K. pneumoniae of ST258, in the
region. The carbapenemase genes responsible for carba-
penem resistance were blaKPC-2 and blaKPC-3 in more
than 90% of all CPE in this study.16 Patients with CPE
infection and/or colonization have been recognized in
both community hospitals as well as tertiary care hospi-
tals in the CRACKLE study.
In the most recent assessment from the CDC, KPC-
producing CPE have been reported from every state in
the United States except for Maine and Idaho.24 None-
theless, infections caused by KPC-producing CPE
remain a very small subset of all infections caused by
Enterobacteriaceae in the US. In a CDC study spanning
2012–2013, the incidence of CRE in 7 US communities
was estimated between 0.35 and 4.80 annual incident
CRE cases/100,000 population, with an overall estimate
of 2.94 annual incident CRE cases/100,000 population.25
However, these data are limited by the small number of
CRE isolates that were confirmed to be CPE. Less than a
third of CRE isolates were available for testing. Of these
188 isolates, 47% tested positive for a carbapenemase
and the only identified carbapenemases were part of the
KPC family.25 Detailed data on the incidence of KPC-
producing CPE in the US remain scarce.
KPC-producing CPE are also widespread in South
and Central America. Several studies have described
their epidemiology in Colombia.26-28 For example, a
recent 2 y (2012–2014) surveillance study in 5 hospitals
– sized between 140 and 754 beds – in Medellin revealed
that 166 patients had KPC-producing CPE during the
study period. Of interest, a high frequency of non-ST258
(62%) was found in this study.29 In a multi-national
observational study spanning 7 Latin American nations
(Argentina, Colombia, Ecuador, Guatemala, Mexico,
Peru and Venezuela), 255 patients with bloodstream
infections caused by Enterobacteriaceae were included.
Of these patients, 21% had a CPE, which were mostly
KPC producers (83%).30 As in most series of CPE infec-
tions, K. pneumoniae was the most commonly isolated
Enterobacteriaceae species. Similar to the US, it is diffi-
cult to reliably estimate the exact incidence of CPE infec-
tions in various Latin American countries.
In Europe, the highest incidence of KPC-producing
CPE is found in Mediterranean countries, especially Italy
and Greece.31 These 2 countries were the only 2
European countries reported to have an “endemic situa-
tion” for KPC in 2014–2015.31 While other carbapene-
mases are present in Italy and Greece, KPC remains the
most common etiology of carbapenem resistance.31 In a
single-center study from Italy that reported on CPKP
during 2012–2014, 432 of a total of 436 carbapenemase-
producing strains were found to produce KPC.32 In a
large, retrospective, multi-center study conducted in 5
Italian hospitals, 661 patients with KPC-producing K.
pneumoniae were included over a 4 y period. Of these,
the majority carried blaKPC-3 (75%), and the remainder
carried blaKPC-2.
33 These were selected from a total of
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3,449 patients with culture positivity for KPC-producing
K. pneumoniae. In other words, on average around 170
patients had positive cultures for KPC-producing K.
pneumoniae per participating hospital per year.33 The
impact of KPC in Greece has been similarly dramatic. In
a 10-year single-center study, a large increase in the
number of KPC-producing K. pneumoniae cases was
reported.34 Prior to 2008, no KPC producers were found.
From 2008 onwards, the prevalence of KPC producers
increased and by 2014 the majority of K. pneumoniae
isolates carried a blaKPC gene.
34 In addition, the overall
rate of carbapenemase-producing K. pneumoniae blood-
stream infection (BSI) increased from 0.5 cases per
10,000 patient-days in 2005 to 4.2 cases per 10,000
patient-days, while non-carbapenemase-producing K.
pneumoniae BSI rates did not decrease.34
In the Middle East, a significant epidemic of KPC-pro-
ducing CPE has evolved. Of note, a national interventional
strategy to contain the spread of CPE within Israel was
started in 2007 after a large spike in the number of such
cases was detected nationwide. This successful intervention
resulted in a dramatic drop of hospital-acquired CPE cases
from 55.5 to 4.8 cases/100,000 patient-days.35 Unfortu-
nately, ongoing unrest in the Middle East threatens these
advances, as exemplified by the finding of CPE in wounded
Syrian patients admitted to northern Israeli hospitals.36
KPC enzymes have also been reported in Asia, espe-
cially China. In a study of carbapenem-resistant E. coli
strains from Shanghai, the majority of CPE (13/16) pro-
duced KPC.37 When patients at a Chinese tertiary care
hospital were screened for CRE rectal carriage in a 2011–
2012 study, 4 of 303 were found to have KPC-producing
Enterobacteriaceae.38 In a study from 2011, blaKPC-2 was
present in 71% of 109 ertapenem-resistant K. pneumo-
niae isolates, often in combination with CTX-M type
ESBL enzymes.39 The Chinese report of blaKPC-2 in a
hypervirulent K1 strain is especially concerning as it may
be the harbinger of the spread of strains that combine
hypervirulence with carbapenem resistance.40 In con-
trast, blaKPC has been infrequently found in Enterobac-
teriaceae from patients in India, where NDM-type MBL
is the predominant carbapenemase.41,42
Few data are available regarding the epidemiology of
KPC in Africa. A single-center study from Tanzania
indicated that KPC was an unusual etiology for carbape-
nem resistance; among 29 carbapenemase-producing K.
pneumoniae, only 3 were KPC producers.43 KPC pro-
ducers have also been reported from South Africa.44
Where are MBL-producing CPE found?
The substantial burden of carbapenemases in the MBL
class appears to lie in Asia. Especially, the New Delhi
Metallo-b-lactamases (NDM) are of concern in this region.
The first patient in whom blaNDM-1 was detected was a
Swedish patient who traveled to India in 2007, and
acquired a K. pneumoniae urinary tract infection. This iso-
late displayed carbapenem resistance that was mediated
through production of a novel carbapenemase designated
NDM-1.45 A follow-up study showed that NDM-1-medi-
ated carbapenem resistance was widespread in India,
Pakistan, and Bangladesh.46 Since then, blaNDM-positive
Enterobacteriaceae have become increasingly common in
India. Of note, blaNDM-1 carrying CPE were not only iso-
lated from patients in India, but importantly also in public
tap water and seepage water.47 In a recent study from
Mumbai, out of 111 CPE, 106 were NDM producers. In
addition, 21 NDM producers were found to produce addi-
tional carbapenemases as well (17 isolates were positive for
OXA-48-type carbapenemase and 4 for VIM-type MBL).41
Of great concern, they have also been recognized as a
source of community-associated infections.48 NDM pro-
ducers have also been described in Enterobacteriaceae in
China, but appear to be less widespread as compared to
India. In a multicenter study looking at 90 patients with E.
coli BSI in Shanghai between 2013–2014, no NDM pro-
ducers were found.49 Similarly, in an evaluation of 71 CRE
from Hong Kong from 2010–2012, only 9 were confirmed
to be CPE. Of these 9 isolates, 3 produced IMP-4, 3 NDM-
1 and 3 KPC-2.50 A recent worrying observation is the co-
localization of blaNDM-9 and the plasmid-mediated colistin
resistance gene mcr-1 within an E. coli strain recovered
from chicken meat sold in Guangzhou, China.51
In Europe, NDM producers are most commonly found
in Romania, Poland and Denmark, where “inter-regional
spread” (epidemiological stage 4) is deemed to be present.31
A large national Polish study from 2012–2014 identified
374 patients with NDM-producing CPE.52 Most of these
cases were epidemiologically linked and thought to be part
of a large multi-regional, multi-center outbreak. Outbreak
isolates includedK. pneumoniae and E. coli, and several con-
tained similar transposons.52 In Spain, Italy and Hungary,
VIM is the predominant MBL; in these countries, “inter-
regional spread” (epidemiological stage 4) of VIMproducers
has been documented.31 In addition, contact with healthcare
in countries that are endemic for NDM-producers such as
India, has been linked to cases presenting in the UK and
other European countries.53
In the US and Canada, MBL have remained an
uncommon etiology for carbapenem resistance in Enter-
obacteriaceae.54 In 2012, an outbreak of blaNDM-1 pro-
ducing K. pneumoniae was reported from Denver.
Routes of transmission were speculated to include colo-
nized patients who went undetected. The route of intro-
duction into the Denver healthcare system was not
established.55 As of April 2016, 157 NDM-producing
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CPE from 25 states were reported to the CDC.24 A recent
outbreak from Illinois of NDM-producing CPE was
found to be associated with the use of endoscopes.56
VIM-producing and IMP-producing CPE are even less
common; per the CDC, only 17 isolates from 7 states;
and 10 isolates from 5 states have been reported as of
April 2016, respectively.24
MBL-producing Enterobacteriaceae isolates have also
been reported from several Latin American countries. In a
multinational survey spanning 2012–2014, VIM-producing
CPE were recovered from Mexico and NDM-1-producing
CPE from Venezuela.57 As noted above, KPC enzymes are
the most common etiology of carbapenem resistance in
Latin America; in the observational multi-national study on
CPE BSI in 7 Latin American nations, 9% and 8% of CPE
harbored blaVIM and blaNDM, respectively.
30 Similarly, in a
multi-center Colombian study of 193 carbapenem-resistant
K. pneumoniae isolates, only 1 isolates was found to be pos-
itive for an MBL gene (blaVIM).
29 MBL-producing CPE
have also been reported from Brazil.58 Of concern, blaNDM-
1 was found in the water near Rio de Janeiro in the time
period leading up to the 2016 Olympics.59
MBL enzymes have been reported in CPE recovered
from patients in various African countries for the past
decade or so. However, the current magnitude of the MBL-
mediated CPE epidemic in Africa is difficult to estimate
due to scarcity of data. In a multinational survey spanning
2012–2014, NDM-producing CPE were recovered from
Kenya, Nigeria and South Africa and VIM-producing CPE
from Nigeria and South Africa.57 In an early report from
Tunisia, 11 patients admitted in 2005 with VIM-4-produc-
ing CPE were described.60 A more recent study evaluating
bacteria recovered from 2 polluted Tunisian rivers in 2010
documented the frequent occurrence of VIM and IMP
enzymes in K. pneumoniae isolates.61 The first recognized
occurrence of NDM-1 in South Africa was in 2010.62 This
first case has been followed by several others from South
Africa, raising concerns that NDM-producing CPE are
becoming endemic.63,64 Risk factors for acquisition of
NDM-producing CPE in South Africa were similar to other
reports and included comorbid conditions, mechanical ven-
tilation, and prior use of piperacillin-tazobactam.64 Of note,
both local and imported cases of NDM-1 producing CPE
seem to occur in South Africa.63 VIM-1-producing CPE
have also been described from South Africa.65 In addition,
NDM enzymes have been reported from several other Afri-
can countries including Egypt, Morocco, Algeria, Kenya,
Cameroon and Tanzania.43,66-70
Where are OXA-producing CPE found?
OXA-48-like carbapenemases remain extremely rare as a
cause of carbapenem resistance in Enterobacteriaceae in
the US.71 Per CDC data, OXA-48-like-producing CPE
were detected only in 43 patients from 19 states as of
August 2015.71 In contrast, they are relatively commonly
found in Europe, especially in Mediterranean countries.20
The first reported OXA-48-producing Enterobacteriaceae
was a Klebsiella pneumoniae strain that was isolated in
Turkey in 2001.72 OXA-48-like producing Klebsiella pneu-
moniae clones have persisted in Turkey as a cause of noso-
comial infections. Turkey was reported as having the
highest epidemiologic level (stage 5 “endemic situation”) of
these strains in 2014–2015.31 In a recent study from
Turkey, 92% of CPE were OXA-48-like producers.73 In
Spain, France, Belgium and Romania, the epidemiologic
stage was deemed “inter-regional spread,” or stage 4, in
2014–2015.31 In addition to Europe, OXA-48-like enzymes
have been found worldwide in Enterobacteriaceae. Exam-
ples of areas with spread of OXA-48-like producing CPE
include the Middle East (e.g., United Arab Emirates, Saudi
Arabia, Lebanon, Israel), Africa (e.g., Libya, Egypt, Algeria,
Morocco, South Africa), Asia (e.g., Russia, India, China,
Taiwan, Thailand), and South America (e.g., Argentina,
Brazil, Colombia).29,74-89 It is important to note that, since
most clinical microbiology laboratories do not test for the
presence of OXA-48-like enzymes and the associated phe-
notype (i.e., low-level carbapenem resistance) may be diffi-
cult to recognize, the incidence of OXA-48-like-producing
CPE is likely underestimated.
Who is at risk for acquiring CPE?
Safdar and Maki outlined a framework for the common-
ality of risk factors for the acquisition of MDR organisms
in their landmark article.90 This framework applies to the
acquisition of CPE as well. Similar to other MDR bacte-
ria, important risk factors for colonization with CPE
include prior antibiotic usage, healthcare and long term
care exposure, chronic comorbid conditions, and the
presence of invasive catheters and drains.16,25,91-95 A
potential common pathway for these risk factors – in
addition to the obvious increased risk of exposure to
other patients and/or healthcare workers who are colo-
nized with CPE – is the disturbance of the microbiome.96
Accordingly, in the CRACKLE study patients were
elderly; the median age of patients with carbapenem-
resistant K. pneumoniae was 70 y (interquartile range
[IQR] 58–81 years).16 A slight female predominance was
observed; 60% of patients were women. Comorbid con-
ditions were common; 56% had a documented history of
diabetes mellitus, 57% had heart disease, 26% of patients
carried the diagnosis of renal insufficiency. The median
Charlson Comorbidity Index was 4 (IQR 2–6).16 Simi-
larly, patients with CDC-defined CRE had a median age
of 66 (with a range of <1 to 100), 59% were female. In
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the CDC study, a lower Charlson Comorbidity Index was
noted (a median of 2, with a range of 0–12), perhaps as a
consequence of a lower percentage of patients included
in the study who had carbapenemase-producing CRE.
Still only 9% of patients did not have any underlying
condition. Indwelling devices were also common in this
CDC study, 75% of patients had a urinary catheter in
place, 43% a central venous catheter, and 39% a feeding
tube.25 In addition to these traditional risk factors, travel
to endemic areas is obviously an important risk factor.97
Especially healthcare exposure in endemic areas includ-
ing “medical tourism” plays an important role in the
spread of CPE.97
Conclusions
Carbapenemases have a global distribution, but substan-
tial variability exists on the continental, national,
regional, and even center-to-center levels. Awareness of
the prevalence and incidence of the specific mechanisms
of carbapenem resistance within Enterobacteriaceae is
crucial in the prevention of their spread and selection of
appropriate treatment options.
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